5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 7.09▼ | 7.09▼ | 7.10▼ | 7.55▼ | 7.84▼ |
MA10 | 7.09▼ | 7.14▼ | 7.29▼ | 7.61▼ | 8.49▼ |
MA20 | 7.10▼ | 7.33▼ | 7.43▼ | 7.94▼ | 6.99▲ |
MA50 | 7.33▼ | 7.58▼ | 7.54▼ | 8.74▼ | 9.60▼ |
MA100 | 7.55▼ | 7.61▼ | 7.72▼ | 6.63▲ | N/A |
MA200 | 7.54▼ | 7.91▼ | 8.35▼ | 8.48▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.016▲ | -0.020▼ | -0.047▼ | -0.031▼ | 0.165▲ |
RSI | 41.099▼ | 33.369▼ | 34.303▼ | 38.706▼ | 47.498▼ |
STOCH | 49.912 | 15.451▼ | 6.136▼ | 33.559 | 16.169▼ |
WILL %R | -50.000 | -89.928▼ | -89.928▼ | -92.500▼ | -65.379 |
CCI | 16.000 | -60.497 | -88.099 | -132.016▼ | -84.661 |
Sunday, May 18, 2025 01:05 PM
Short interest in CervoMed Inc (NASDAQ:CRVO) decreased during the last reporting period, falling from 971.78K to 903.86K. This put 15.59% of the company's publicly available shares short.
|
Tuesday, May 13, 2025 05:01 PM
CervoMed (NASDAQ:CRVO – Get Free Report) had its price target hoisted by equities researchers at Chardan Capital from $14.00 to $15.00 in a research note issued on Monday,Benzinga reports.
|
Monday, May 12, 2025 06:16 AM
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago. These figures ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 7.45 | 7.62 | 7.00 | 7.12 | 143,143 |
12/06/25 | 7.39 | 7.76 | 7.29 | 7.62 | 50,578 |
11/06/25 | 7.85 | 8.03 | 7.30 | 7.47 | 116,563 |
10/06/25 | 8.17 | 8.175 | 7.75 | 7.78 | 114,739 |
09/06/25 | 7.75 | 7.95 | 7.54 | 7.74 | 85,289 |
06/06/25 | 7.63 | 7.68 | 7.31 | 7.62 | 93,144 |
05/06/25 | 7.38 | 7.69 | 7.20 | 7.54 | 98,720 |
04/06/25 | 7.57 | 7.71 | 7.30 | 7.48 | 125,914 |
03/06/25 | 8.02 | 8.374 | 7.55 | 7.59 | 162,718 |
02/06/25 | 7.18 | 8.60 | 7.18 | 8.16 | 282,209 |
|
|
||||
|
|
||||
|
|